Literature DB >> 4443807

Buccal absorption of ergotamine.

J M Sutherland, W D Hooper, M J Eadie, J H Tyrer.   

Abstract

The rate of disappearance of ergotamine from the mouth after buccal administration has been studied in seven subjects. Allowance has been made for non-absorptive losses of the drug due to experimental technique. The absorption of ergotamine across the buccal mucosa appears to be a passive process, pH-dependent but independent of ergotamine concentration or the simultaneous presence of caffeine. Because of the low solubility of ergotamine at the pH of saliva, it is unlikely that therapeutically useful amounts of the drug would have absorbed across the buccal mucosa even after the drug had been in the mouth for five minutes.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4443807      PMCID: PMC494854          DOI: 10.1136/jnnp.37.10.1116

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  12 in total

1.  CLINICAL TRIAL OF INHALED ERGOTAMINE TARTRATE IN MIGRAINE.

Authors:  J CROOKS; S A STEPHEN; W BRASS
Journal:  Br Med J       Date:  1964-01-25

Review 2.  ABSORPTION OF DRUGS THROUGH THE ORAL MUCOSA.

Authors:  M GIBALDI; J L KANIG
Journal:  J Oral Ther Pharmacol       Date:  1965-01

3.  The drug therapy of migraine.

Authors:  J M SUTHERLAND; M J EADIE
Journal:  Med J Aust       Date:  1961-11-04       Impact factor: 7.738

4.  Aerosol ergotamine tartrate for migraine and Horton's syndrome.

Authors:  J R GRAHAM; B P MALVEA; H F GRAMM
Journal:  N Engl J Med       Date:  1960-10-20       Impact factor: 91.245

5.  Recent advances in treatment of migraine.

Authors:  A P FRIEDMAN; T J C VON STORCH
Journal:  J Am Med Assoc       Date:  1951-04-28

6.  Fluorimetric assay of ergotamine.

Authors:  W D Hooper; J M Sutherland; M J Eadie; J H Tyrer
Journal:  Anal Chim Acta       Date:  1974-03       Impact factor: 6.558

7.  The influence of alkyl substitution in acids on their performance in the buccal absorption test.

Authors:  A H Beckett; A C Moffat
Journal:  J Pharm Pharmacol       Date:  1968-12       Impact factor: 3.765

8.  Physical chemistry of ergot alkaloids and derivatives. I. Ionization constants of several medicinally active bases.

Authors:  H V Maulding; M A Zoglio
Journal:  J Pharm Sci       Date:  1970-05       Impact factor: 3.534

9.  Complexes of ergot alkaloids and derivatives. I. The interaction of caffeine with ergotamine tartrate in aqueous solution.

Authors:  M A Zoglio; H V Maulding; J J Windheuser
Journal:  J Pharm Sci       Date:  1969-02       Impact factor: 3.534

10.  TREATMENT OF MIGRAINE-Results with Dihydroergocornine Methanesulfonate (DHO-180) and Other Ergot Derivatives.

Authors:  N A Bercel
Journal:  Calif Med       Date:  1950-04
View more
  2 in total

1.  Bioavailability of sublingual ergotamine.

Authors:  P Tfelt-Hansen; L Paalzow; J J Ibraheem
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of ergotamine in migraine and cluster headache.

Authors:  V L Perrin
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.